Lilly's Foundayo shows superior results in Phase 3 trial for type 2 diabetes
The superior performance of Foundayo in Phase 3 trials positions Eli Lilly to potentially redefine the oral incretin therapy market. This development may compel competitors to innovate or adjust their strategies in response to Lilly's advancements.
| Drug | MOA / Company | Stage |
|---|---|---|
| Foundayo | Eli Lilly | Lead |
| Endocrinology | — | Competing |
Focal Asset
Foundayo
Company
Eli Lilly
Indication
Endocrinology / Type 2 Diabetes
Signal Score
8.4
Signal assessment
Signal strength
high
Confidence level
high
Strategic implication
The superior performance of Foundayo in Phase 3 trials positions Eli Lilly to potentially redefine the oral incretin therapy market. This development may compel competitors to innovate or adjust their strategies in response to Lilly's advancements.
Why it matters
The superior performance of Foundayo in Phase 3 trials positions Eli Lilly to potentially redefine the oral incretin therapy market. This development may compel competitors to innovate or adjust their strategies in response to Lilly's advancements.
What changed
Trial Update
Analysis
Phase 3 ACHIEVE results indicate Foundayo outperformed oral semaglutide and dapagliflozin in treating type 2 diabetes.
The superior performance of Foundayo in Phase 3 trials positions Eli Lilly to potentially redefine the oral incretin therapy market. This development may compel competitors to innovate or adjust their strategies in response to Lilly's advancements.
Monitor further data releases and regulatory submissions for Foundayo, as well as competitor responses.
Related companies & assets
Companies
Sources & Humanexa intelligence
Source links
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.